Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
Palmieri R, Buccisano F, Arena V, Irno Consalvo MA, Piciocchi A, Maurillo L, DelPrincipe MI, Di Veroli A, Paterno G, Conti C, Fraboni D, Voso MT, Arcese W, Venditti A. Palmieri R, et al. Among authors: di veroli a. Leuk Lymphoma. 2022 Apr;63(4):996-1000. doi: 10.1080/10428194.2021.2005042. Epub 2021 Nov 21. Leuk Lymphoma. 2022. PMID: 34806525 No abstract available.
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.
Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A. Sarlo C, et al. Among authors: di caprio l, di veroli a. Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28. Leuk Res Treatment. 2013. PMID: 23738080 Free PMC article.
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.
Del Principe MI, Buccisano F, Maurillo L, Venditti D, Cefalo M, Sarlo C, Di Caprio L, Di Veroli A, Nasso D, Ceresoli E, Postorino M, Di Piazza F, Colandrea G, Conti F, Del Poeta G, Amadori S, Venditti A. Del Principe MI, et al. Among authors: di piazza f, di caprio l, di veroli a. Thromb Res. 2013 Nov;132(5):511-4. doi: 10.1016/j.thromres.2013.08.007. Epub 2013 Aug 16. Thromb Res. 2013. PMID: 24090605
Extensive toxic epidermal necrolysis following brentuximab vedotin administration.
Del Principe MI, Sconocchia G, Buccisano F, Cefalo M, Di Veroli A, De Santis G, Nasso D, Maurillo L, Anemona L, Postorino M, Del Poeta G, Amadori S, Venditti A. Del Principe MI, et al. Among authors: di veroli a. Ann Hematol. 2015 Feb;94(2):355-6. doi: 10.1007/s00277-014-2148-3. Epub 2014 Jul 2. Ann Hematol. 2015. PMID: 24981690 No abstract available.
Reversible hyporegenerative anemia during natalizumab treatment.
Monteleone F, Buccisano F, Boffa L, Buttari F, Di Veroli A, Borriello G, Rossi S, Centonze D. Monteleone F, et al. Among authors: di veroli a. Mult Scler. 2015 Feb;21(2):257-8. doi: 10.1177/1352458514546516. Epub 2014 Sep 3. Mult Scler. 2015. PMID: 25186208 No abstract available.
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P, Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, Sconocchia G, Lo-Coco F, Amadori S, Venditti A. Maurillo L, et al. Among authors: di veroli a. Am J Hematol. 2015 Feb;90(2):125-31. doi: 10.1002/ajh.23893. Epub 2014 Nov 24. Am J Hematol. 2015. PMID: 25377359 Free article. Clinical Trial.
Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.
Del Principe MI, Maurillo L, Buccisano F, Sconocchia G, Cefalo M, De Santis G, Di Veroli A, Ditto C, Nasso D, Postorino M, Refrigeri M, Attrotto C, Del Poeta G, Lo-Coco F, Amadori S, Venditti A. Del Principe MI, et al. Among authors: di veroli a. Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014075. doi: 10.4084/MJHID.2014.075. eCollection 2014. Mediterr J Hematol Infect Dis. 2014. PMID: 25408861 Free PMC article. Review.
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.
Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A. Buccisano F, et al. Among authors: di veroli a. Ann Hematol. 2015 Aug;94(8):1319-26. doi: 10.1007/s00277-015-2364-5. Epub 2015 Apr 14. Ann Hematol. 2015. PMID: 25869029
71 results